Abstract: An interface layout method, apparatus, and system are described. A first terminal device receives a screen projection instruction that is used to instruct the first terminal device to perform screen projection to a second terminal device. The first terminal device generates, based on interface information of a first interface and second device information, a second interface to be displayed on the second terminal device, where the first interface is an interface displayed on the first terminal device. The second device information is used to indicate a screen size and a screen status of the second terminal device.

Abstract: An image processing method includes: acquiring first image data of a first image, the first image data including pixel values of a plurality of pixels in the first image; a first compression-allowed region existing in the first image, obtaining region expression information of the first compression-allowed region, the first compression-allowed region including a region where a plurality of first pixels are located, and a difference between pixel values of any two first pixels in the plurality of first pixels being within a preset range; determining a region pixel value of the first compression-allowed region according to a pixel value of at least one first pixel in the first compression-allowed region; and generating second image data of the first image, the second image data including region expression information and the region pixel value of the first compression-allowed region.

Abstract: A data transmission method, includes: receiving N data packets sent by a communication opposite-end device, wherein each data packet includes a piece of target data, and N is a positive integer greater than 1; according to a receiving sequence of the N data packets from a first data packet to an Nth data packet, sequentially determining whether a transmission error occurs in each data packet; if it is determined that a data packet is transmitted incorrectly, storing, in a first queue, a piece of first indication information which indicates the data packet is transmitted incorrectly; and after it is determined that the reception of the N data packets ends, generating a first retransmission instruction, and sending the first retransmission instruction to the communication opposite-end device, wherein the first retransmission instruction includes information in the first queue.

Abstract: A three-dimensional scene constructing method, apparatus and system, and a storage medium. The three-dimensional scene constructing method includes: acquiring point cloud data of a key object and a background object in a target scene, wherein the point cloud data of the key object comprises three-dimensional information and corresponding feature information, and the point cloud data of the background object at least comprises three-dimensional information; establishing a feature database of the target scene, wherein the feature database at least comprises a key object feature library for recording three-dimensional information and feature information of the key object; performing registration and fusion on the point cloud data of the key object and the point cloud data of the background object, so as to obtain a three-dimensional model of the target scene; and when updating the three-dimensional model, reconstructing the three-dimensional model in a regional manner according to the feature database.

Abstract: Disclosed are a pharmaceutical composition and an application thereof. The pharmaceutical composition of the present invention comprises the following components in parts by weight: 2-20 parts of phenolic acids, 0.5-5 parts of flavonoids, 0.005-0.5 part of tanshinones, 5-20 parts of saponins, and 10-18 parts of volatile oils. The pharmaceutical composition has the functions of protecting against myocardial damage and treating heart failure.

Abstract: It is disclosed a method, an apparatus, a computing device, and a computer-readable storage medium for identifying a signal. The method includes demodulating a modulated signal to generate a transmission signal, transmitting the transmission signal, receiving an echo signal generated by a reflection of the transmission signal, demodulating the echo signal to obtain demodulated information, identifying the demodulated information by using a target network model to obtain an identification result of the echo signal, and outputting the identification result to a graphical user interface for display.

Abstract: An image processing controller for a display device includes a fixed-point circuitry and a plurality of neural network blocks cascaded sequentially. The fixed-point circuitry is electrically connected to each neural network block, and configured to receive a feature signal corresponding to an output feature map about the display device from each neural network block, perform fixed-point processing on the feature signal to acquire fixed-point data within a design accuracy range, and input the fixed-point data as an input feature map to a next-level neural network block.

Abstract: A pharmaceutical composition is prepared from the following raw materials (in parts by weight): silybin (8.75-60), phospholipid (15-65), a Pu'er tea extract (25-200), and vitamin E (6.25-40). The composition has the effect of treating non-alcoholic fatty liver diseases.

Abstract: A pharmaceutical composition is prepared from the following raw materials (in parts by weight): silybin (8.75-60), phospholipid (15-65), a Pu'er tea extract (25-200), and vitamin E (6.25-40). The composition has the effect of treating non-alcoholic fatty liver diseases.

Abstract: The embodiment of the present disclosure provides a positioning method, a positioning device and system, an electronic equipment and a computer readable medium. The positioning method comprises: establishing connection with a target node in response to feedback information returned by the target node; acquiring initial position information; acquiring real-time position information for multiple times; and positioning the target node according to the acquired initial position information and the real-time position information acquired for multiple times. wherein the real-time position information comprises the direction and the distance of the movement of the source node relative to the last position of the source node, the direction and the distance of the movement of the target node returned by the target node relative to the last position of the target node, and the distance between the target node and the source node.

Abstract: The present disclosure discloses a preparation method of a energetic metal coordination compound with 5-methyltetrazole, belonging to the technical field of energetic metal coordination compounds. The method comprises: dissolving methyltetrazole in distilled water, and adding a nitrate therein, to obtain a mixture; stirring the mixture for 30 min, then putting the mixture into a teflon-lined reactor, and reacting at a constant temperature of 120±1° C. for 72 h, to obtain a crude reaction product; cooling the crude reaction product to 80° C., thermally insulating for 12 h, and hereafter cooling to room temperature at a rate of 3° C./h, to obtain a target product. The coordination compound has a good explosion heat, high thermal stability, and low mechanical sensitivity. The present disclosure could obtain a product with a high yield by a green and environment-friendly method.

Abstract: The present invention discloses a traditional Chinese medicinal composition for preventing and/or treating ischemia reperfusion injury; the traditional Chinese medicinal composition consists of salvianolic acids, Panax notoginseng saponins and total saponins of Astragalus.

Abstract: The present disclosure discloses a preparation method of a energetic metal coordination compound with 5-methyltetrazole, belonging to the technical field of energetic metal coordination compounds. The method comprises: dissolving methyltetrazole in distilled water, and adding a nitrate therein, to obtain a mixture; stirring the mixture for 30 min, then putting the mixture into a teflon-lined reactor, and reacting at a constant temperature of 120±1° C. for 72 h, to obtain a crude reaction product; cooling the crude reaction product to 80° C., thermally insulating for 12 h, and hereafter cooling to room temperature at a rate of 3° C./h, to obtain a target product. The coordination compound has a good explosion heat, high thermal stability, and low mechanical sensitivity. The present disclosure could obtain a product with a high yield by a green and environment-friendly method.

Abstract: The present invention belongs to the technical field of biological pharmacy, and particularly relates to a long-acting HM-3 fusion protein molecule and an application thereof. In the present invention, on the basis of the sequence of HM-3 molecule, an active polypeptide HM-3 and derivatives thereof are linked to a human Fc (IgG) fragment or a fragment of an Fc (IgG) mutant directly or by a linker peptide (Linker), thus forming a novel molecular entity. The general formula of the molecular entity is (HM-3)n-Linker-Fc(IgG), Fc(IgG)-Linker-(HM-3)n, or (HM-3)n-Linker-Fc(IgG)-Linker-(HM-3)n. The fusion protein effectively prolongs the half-life of HM-3, is low in cost and overcomes the major problem of druggability of small peptides. Therefore, the fusion protein of the present invention may serve as a potential drug for the treatment of autoimmune diseases, neovascular diseases, osteoarthritis and the like.

Abstract: Disclosed are a pharmaceutical composition and an application thereof. The pharmaceutical composition of the present invention comprises the following components in parts by weight: 2-20 parts of phenolic acids, 0.5-5 parts of flavonoids, 0.005-0.5 part of tanshinones, 5-20 parts of saponins, and 10-18 parts of volatile oils. The pharmaceutical composition has the functions of protecting against myocardial damage and treating heart failure.

Abstract: Disclosed is an application of substituted cinnamamide derivatives in the preparation of anti-anxiety medications, the substituted cinnammide derivatives are compounds having the structure of formula (I) or pharmaceutically acceptable salts thereof, wherein, R1 is —H, —OH, —F, —Cl, —Br, —I, —OCH3, —OCF3, —OCHF2, —OCH2F, —CF3, —CHF2, —CH2F, —CH3, —CH3CH2, —CF3CH2, —CN, —NO2, —NH2 or —COOR5; R2 is H, C1-C10 linear alkyl, C3-C10 branched alkyl, C3-C10 cyclic alkyl, C1-C10 hydroxyalkyl or a N-substituted piperazine-derived group; or R2 is a group forming with adjacent Y a tetrahydropyrrolyl group, a piperidyl group or a cyclohexanimido group.

Abstract: The present invention relates to the medical field, specifically a salvianolic acid T as described in structural formula (I), a chiral isomer thereof, a preparation method therefor, pharmaceutical compositions, antioxidants, and free radical scavengers thereof, and a use of the compound.

Abstract: Disclosed is a pharmaceutical composition containing silibinin, which is prepared from the following bulk drugs by weight ratio: 8.75-60 parts of silibinin, 15-65 parts of phospholipid, and 25-200 parts of Pu'er tea extract. The drug has the function of treating non-alcoholic fatty liver.

Abstract: The invention relates to a method of treatment comprising administering a long-acting mutant human fibroblast growth factor to a subject in need thereof. The said long-acting mutant human fibroblast growth factor is mPEG-CH2—N?H-mFGF21, wherein mFGF21 consists of SEQ ID NO:1, and the said new use consists of a method of treating non-alcoholic steatohepatitis.

Abstract: Disclosed are a pharmaceutical composition for treating non-alcoholic fatty liver and a method for preparing same. The composition is prepared from the following hulk drugs by weight ratio: 8.75-60 parts of silibinin, 15-65 parts of phospholipid, 25-200 parts of Pu'er tea extract, and 5-50 parts of radix puerariae extract.